Plunkett Research Online: Audentes Therapeutics Inc

AUDENTES THERAPEUTICS INC (BOLD:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Audentes Therapeutics, Inc. is a biotechnology company committed to the development and commercialization of innovative gene therapy treatments for people with serious rare diseases. The firm currently has four programs in development: AT132 for the treatment of X-Linked Myotubular Myopathy, which .....



Audentes Therapeutics Inc
Ticker: BOLD
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 415-818-1001
Fax:
Address: 600 California Street
17th Floor
San Francisc, CA 94108 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Gene Therapy Preparations Manufacturing
ContactsDescription
Matthew PattersonCEO/Co-Founder/Director
Thomas SolowayCFO/Chief Accounting Officer/Senior VP
See More
Audentes Therapeutics, Inc. is a biotechnology company committed to the development and commercialization of innovative gene therapy treatments for people with serious rare diseases. The firm currently has four programs in development: AT132 for the treatment of X-Linked Myotubular Myopathy, which .....See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
20172016201520142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
AT132
AT342
AT307
AT982
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: